免疫检查点抑制剂在食管鳞状细胞癌治疗中的应用：我们目前的状况与未来走向？
Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?
作者信息
Chen Ning, Xu Xiaoling, Fan Yun
机构信息
Department of Oncology, The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Department of Medical Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
出版信息
Ther Adv Med Oncol. 2023 Aug 2;15:17588359231189420. doi: 10.1177/17588359231189420. eCollection 2023.
Oesophageal squamous cell carcinoma (ESCC) is a kind of malignant tumour with high invasiveness and a poor prognosis. Immunotherapy, especially immune checkpoint inhibitors (ICIs), is a rapidly growing therapeutic method that activates and enhances anti-tumour immunity to treat patients with malignancy. Several clinical trials have confirmed the efficacy of ICIs in the treatment of ESCC. ICIs have been approved for the treatment of patients with ESCC. However, only a subset of patients can obtain excellent benefits from ICI therapy. In recent years, there has been a growing interest in exploring predictive biomarkers of immunotherapy response. In this review, we highlighted the predictive biomarkers for the prognosis of ESCC patients treated with ICIs and pointed out the existing problems and the direction of future research in this field.
食管鳞状细胞癌（ESCC）是一种具有高侵袭性且预后较差的恶性肿瘤。免疫疗法，尤其是免疫检查点抑制剂（ICIs），是一种迅速发展的治疗方法，可激活并增强抗肿瘤免疫力以治疗恶性肿瘤患者。多项临床试验已证实ICIs在治疗ESCC方面的疗效。ICIs已被批准用于治疗ESCC患者。然而，只有一部分患者能从ICI治疗中获得显著益处。近年来，人们对探索免疫治疗反应的预测生物标志物的兴趣日益浓厚。在本综述中，我们重点介绍了接受ICIs治疗的ESCC患者预后的预测生物标志物，并指出了该领域存在的问题以及未来的研究方向。
Zotero 插件